Latest Articles
Genetic Study of Rare Endometrial Cancer Uncovers Potential Treatments | Newswise - Newswise
Genetic Study of Rare Endometrial Cancer Uncovers Potential Treatments | Newswise Newswise
Published: Jan. 28, 2026, 12:45 a.m.
Genetic Study of Rare Endometrial Cancer Uncovers Potential Treatments - Yale School of Medicine
Genetic Study of Rare Endometrial Cancer Uncovers Potential Treatments Yale School of Medicine
Published: Jan. 26, 2026, 8:48 p.m.
New Genetic Health & Wellness Reports and Features - 23andMe
New Genetic Health & Wellness Reports and Features 23andMe
Published: Dec. 17, 2025, 9:53 p.m.
How ancient genetics may contribute to symptoms of condition - Bournemouth Echo
How ancient genetics may contribute to symptoms of condition Bournemouth Echo
Published: Dec. 7, 2025, 5 a.m.
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study - The Globe and Mail
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study The Globe and Mail
Published: Dec. 5, 2025, 8:38 p.m.
Modern pollutants and ancient genetic variants could explain why some women develop endometriosis - News-Medical
Modern pollutants and ancient genetic variants could explain why some women develop endometriosis News-Medical
Published: Dec. 5, 2025, 6:56 p.m.
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study - Finviz
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study Finviz
Published: Dec. 5, 2025, 5:30 p.m.
Ancient genetics and modern pollutants could provide a clue to endometriosis risk - Medical Xpress
Ancient genetics and modern pollutants could provide a clue to endometriosis risk Medical Xpress
Published: Dec. 4, 2025, 4:40 p.m.
Ancient genetics and modern pollutants could provide a clue to endometriosis risk - Bournemouth University
Ancient genetics and modern pollutants could provide a clue to endometriosis risk Bournemouth University
Published: Dec. 4, 2025, 1:48 p.m.
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia - The Manila Times
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia The Manila Times
Published: Dec. 4, 2025, 1:22 p.m.
Link copied to clipboard!